Myricetin, a natural inhibitor of CD147, increases sensitivity of cisplatin in ovarian cancer

Background Ovarian cancer (OC) is the most lethal gynecological tumor, but it currently lacks effective therapeutic targets. CD147, which is overexpressed in OC, plays a crucial role in promoting malignant progression and is associated with poor prognosis in patients. Therefore, CD147 has been identified as a potential therapeutic target. While strategies to knock out or inhibit CD147 have shown promising results in various tumors, there is a limited amount of research on the development of CD147 inhibitors.